Paolo Bonato, PhD, director of the Motion Analysis Laboratory at Spaulding Rehabilitation Hospital in Boston, has signed a letter of intent to employ Shimmer’s Verisense continuous monitoring platform during his next clinical trial to study motor recovery in stroke survivors, according to a media release from Shimmer.
Shimmer, based in Dublin, Ireland, designed the Verisense wearable sensor platform to reliably capture accurate and complete biometric data, while placing minimum burden on clinical trial sponsors, sites, and participants.
“We are excited to be able to use Shimmer’s new Verisense platform for our stroke study,” Bonato says, in the release. “The platform’s ability to monitor multiple sensors on a participant’s body simultaneously was crucial for this study. With Verisense, we will gain access to all the raw participant data and built-in algorithms will deliver validated metrics.
“Verisense sensors have a six-month battery life and can even be worn in the shower or bath, which will undoubtedly improve patient compliance and data quality,” he adds. “Furthermore, its monitoring dashboard will give us an overview of all the sensors in the study, while also allowing us to drill down to individual devices.”
“I would like to express my deep gratitude to Enterprise Ireland for their support of Shimmer’s Verisense platform for clinical trials, which goes well beyond facilitating this signing. Their financial support of our development effort was integral to our ability to bring this product to market so quickly,” states Geoff Gill, president of Shimmer Americas.
Bonato is also an associate professor in the Department of Physical Medicine and Rehabilitation at Harvard Medical School, and an associate faculty member at the Wyss Institute for Biologically Inspired Engineering, Harvard University.
[Source: Shimmer, Enterprise Ireland]
